CINECA IRIS Institutional Research Information System

MINA, Roberto
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.032
EU - Europa 2.116
AS - Asia 1.399
SA - Sud America 115
OC - Oceania 30
AF - Africa 22
Continente sconosciuto - Info sul continente non disponibili 1
Totale 7.715
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.910
IT - Italia 691
CN - Cina 591
IE - Irlanda 225
FR - Francia 221
JP - Giappone 208
SE - Svezia 181
GB - Regno Unito 145
IN - India 145
SG - Singapore 135
DE - Germania 104
ES - Italia 104
CA - Canada 90
FI - Finlandia 67
VN - Vietnam 67
NL - Olanda 63
HK - Hong Kong 47
BR - Brasile 44
KR - Corea 44
PL - Polonia 44
AT - Austria 42
TR - Turchia 42
CH - Svizzera 40
TW - Taiwan 34
GR - Grecia 32
UA - Ucraina 32
AU - Australia 26
CO - Colombia 22
PT - Portogallo 22
MX - Messico 21
HU - Ungheria 17
IL - Israele 17
AR - Argentina 16
RU - Federazione Russa 15
BE - Belgio 13
CL - Cile 13
DK - Danimarca 11
NO - Norvegia 11
TH - Thailandia 11
KW - Kuwait 9
SN - Senegal 9
UY - Uruguay 9
CZ - Repubblica Ceca 8
SA - Arabia Saudita 8
ID - Indonesia 7
NG - Nigeria 7
RO - Romania 7
PE - Perù 6
QA - Qatar 6
TT - Trinidad e Tobago 6
AE - Emirati Arabi Uniti 4
AM - Armenia 4
BA - Bosnia-Erzegovina 4
IR - Iran 4
PK - Pakistan 4
SI - Slovenia 4
AD - Andorra 3
BG - Bulgaria 3
MY - Malesia 3
NZ - Nuova Zelanda 3
EC - Ecuador 2
EE - Estonia 2
IQ - Iraq 2
JO - Giordania 2
KY - Cayman, isole 2
SK - Slovacchia (Repubblica Slovacca) 2
UZ - Uzbekistan 2
ZA - Sudafrica 2
BD - Bangladesh 1
BO - Bolivia 1
DZ - Algeria 1
ET - Etiopia 1
EU - Europa 1
GL - Groenlandia 1
HR - Croazia 1
IS - Islanda 1
JM - Giamaica 1
LU - Lussemburgo 1
MA - Marocco 1
NP - Nepal 1
PA - Panama 1
PF - Polinesia Francese 1
PH - Filippine 1
PY - Paraguay 1
TN - Tunisia 1
VE - Venezuela 1
Totale 7.715
Salva come PNG Salva come JPEG
Città #
Fairfield 240
Chandler 215
Dublin 213
Redwood City 210
Cambridge 172
Beijing 164
Torino 151
Ashburn 141
Houston 127
Turin 111
Woodbridge 111
Seattle 105
Wilmington 91
Ann Arbor 88
Nyköping 88
Singapore 74
Medford 64
Tokyo 64
Florence 60
Princeton 54
Shanghai 46
New York 42
Los Angeles 40
Portland 40
London 34
Norwalk 34
Dong Ket 33
Paris 31
Boston 30
Minneapolis 30
Vienna 30
Villeurbanne 30
Hangzhou 29
Boardman 28
Guangzhou 28
Baltimore 27
Indianapolis 27
Chicago 25
Nanjing 25
Rochester 25
Helsinki 24
Milan 24
Pisa 24
Duncan 23
Madrid 23
Ottawa 23
San Diego 23
Seoul 23
Toronto 23
Providence 21
Athens 20
Flushing 19
Taipei 19
Philadelphia 18
San Francisco 18
Dearborn 17
Charlotte 16
Columbus 16
St Louis 16
Durham 15
Pittsburgh 15
Raritan 15
Salt Lake City 15
Warsaw 15
Wuhan 15
Atlanta 14
Breda 14
Chengdu 14
Hyderabad 14
Newbury Park 14
Toledo 14
Brzeg 13
Central 13
Jacksonville 13
Xian 13
Grand Rapids 12
Hong Kong 12
Honolulu 12
San Mateo 12
Santiago 12
Amsterdam 11
Budapest 11
Greenville 11
Miami 11
Rome 11
Scarsdale 11
São Paulo 11
Brooklyn 10
Nanchang 10
Para 10
Pune 10
Sanayi 10
Bengaluru 9
Caserta 9
Chongqing 9
Hebei 9
Louisville 9
Montevideo 9
Mumbai 9
Notre Dame 9
Totale 4.052
Salva come PNG Salva come JPEG
Nome #
Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study 2.498
Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma 554
Plasma cell leukemia: update on biology and therapy 547
Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study. 319
Role of consolidation/maintenance therapy in multiple myeloma. 223
Management of older adults with multiple myeloma 212
Pharmacokinetic evaluation of pomalidomide for the treatment of myeloma 201
Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis 175
Anti-CD38 monoclonal antibodies in multiple myeloma: another cook in the kitchen? 152
New pharmacotherapy options for multiple myeloma 149
Emerging drugs and combinations to treat multiple myeloma 141
Therapeutic monoclonal antibodies and antibody products: Current practices and development in multiple myeloma 136
Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies 134
Development and Validation of a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma in a Pooled Dataset of 2,190 Patients 123
Daratumumab-Based Therapy for IgM Multiple Myeloma With Hyperviscosity Syndrome: A Case Report 109
Redefining the treatment paradigm for multiple myeloma 107
CyTOF®: A New Tool to Decipher the Immunomodulatory Activity of Daratumumab 105
A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma 100
Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study 99
Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma 98
Antibody-drug conjugates: when chemotherapy meets immuno-oncology 97
Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents 95
Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents 94
Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: A pooled analysis of two phase i/ii studies 92
First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials 90
Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials 88
Survival of Multiple Myeloma Patients Aged 65-70 Years in the Era of Novel Agents and Autologous Stem Cell Transplantation. A Multicenter Retrospective Collaborative Study of the Japanese Society of Myeloma and the European Myeloma Network. 79
Minimal Residual Disease in Multiple Myeloma: State of the Art and Future Perspectives 68
Gammopatie monoclonali 64
Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study 63
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. 60
Optimal management of elderly patients with myeloma 58
Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma 58
Lenalidomide-prednisone induction followed by lenalidomide-melphalan-prednisone consolidation and lenalidomide-prednisone maintenance in newly diagnosed elderly unfit myeloma patients. 53
Ultra-Low-Dose Whole-Body Computed Tomography Protocol Optimization for Patients With Plasma Cell Disorders: Diagnostic Accuracy and Effective Dose Analysis From a Reference Center 53
Current treatment strategies with lenalidomide in multiple myeloma and future perspectives. 52
Safety of Rapid Daratumumab Infusion: A Retrospective, Multicenter, Real-Life Analysis on 134 Patients With Multiple Myeloma 51
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study 50
Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia. 47
Part II: role of maintenance therapy in transplant-ineligible patients 47
Minimal Residual Disease in Multiple Myeloma: Ready for Prime Time? 47
Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial 47
Approach to the Older Adult With Multiple Myeloma 45
Gammopatie monoclonali 45
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies 45
Should high-risk smouldering multiple myeloma be treated? 35
The role of autologous stem-cell transplantation in multiple myeloma in 2021 31
Haemopoietic diseases: leukaemias and myelomas 28
Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial 26
Is there still a role for stem cell transplantation in multiple myeloma? 26
Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COV 20
Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors 19
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study 19
Lenalidomide-based triplet regimens in first relapsed multiple myeloma patients: real-world evidence from a propensity score matched analysis 16
Multiple myeloma 14
SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort 12
Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing 10
A prospective, multicenter study on hematopoietic stem-cell mobilization with cyclophosphamide plus granulocyte colony-stimulating factor and 'on-demand' plerixafor in multiple myeloma patients treated with novel agents 6
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network 5
A rational approach to functional high-risk myeloma 5
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma 4
Risk of infection in patients with multiple myeloma treated with T-cell redirecting approaches: a call out for clinicians 4
Totale 8.050
Salva come PNG Salva come JPEG
Categoria #
all - tutte 18.592
article - articoli 0
book - libri 0
conference - conferenze 252
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.844
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020558 15 4 16 51 28 40 50 41 173 47 64 29
2020/20211.709 27 66 128 111 177 242 126 195 159 145 145 188
2021/20221.953 121 114 143 160 131 99 286 120 128 138 199 314
2022/20231.791 129 154 138 122 135 260 142 166 190 111 140 104
2023/20241.535 124 160 106 132 123 165 111 130 39 121 131 193
2024/202556 56 0 0 0 0 0 0 0 0 0 0 0
Totale 8.050